Mandate

Vinge advised Valneva SE in connection with its acquisition of Crucell Sweden AB

January 18, 2016

Vinge, in cooperation with Dechert LLP as lead legal advisor, advised Valneva SE in connection with its acquisition of Crucell Sweden AB, the Nordics vaccine distribution business of the seller (Crucell Holland B.V.) and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and, in some countries, diarrhea caused by ETEC. Valneva is a Lyon based biotechnology company listed at Euronext Paris and at the Vienna stock exchange. The consideration amounted to € 45 million and the acquisition was completed on 9 February 2015.

Vinge advised Valneva on Swedish law matters. Vinge’s team consists of M&A partner Peter Sundgren, associates Johanna Wiberg and Kajsa Hallner (M&A), Anders Morén and Josefin Larsson (banking & finance), and Amanda Knutsson and David Andersson (capital markets).

Related

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge advises Studentbostäder i Norden AB (publ) in connection with its issuance of bonds in an amount of SEK 500 million and its early redemption of outstanding bonds

Vinge has advised Studentbostäder i Norden AB (publ) in connection with its issuance of senior unsecured bonds in an amount of SEK 500 million (within a framework of SEK 750 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
March 12, 2026